The Impact of Recombinant Human Erythropoietin Administration in Critically ill COVID-19 Patients: A Multicenter Cohort Study

The Impact of Recombinant Human Erythropoietin Administration in Critically ill COVID-19 Patients: A Multicenter Cohort Study

The use of erythropoietin-stimulating agents (ESAs) as adjunctive therapy in critically ill patients with COVID-19 may have a potential benefit. This study aims to evaluate the effect of ESAs on the clinical outcomes of critically ill COVID-19 patients. A multicenter, retrospective cohort study was...

Full description

Bibliographic Details
Main Authors: Khalid Al Sulaiman BCCCP, BCNSP, MBA, FCCM, Ohoud Aljuhani Pharm.D, BCCCP, Ghazwa B. Korayem Pharm.D, Ali F. Altebainawi Pharm.D, Ramesh Vishwakarma PhD, Mashael AlFaifi Pharm.D, Samiah Alsohimi Pharm.D, Aljoharah Alrayes Pharm.D, Sara Albishi Pharm.D, Reem Alqahtani Pharm.D, Mai Alalawi Pharm.D, Ibrahim Al Sulaihim MSc, Thamer A. Alanazi BSc, Rahaf A. Alqahtani Pharm.D, Alaa Almagthali Pharm.D, Shahamah Jomah BSc, Areej Alshlowi BSc, Tahani R. Alshammari BSc, Shahad S. Alzahrani Pharm.D, Marwa I. Abdulqader Pharm.D
Format: Article
Language:English
Published: SAGE Publishing 2023-12-01
Series:Clinical and Applied Thrombosis/Hemostasis
Online Access:https://doi.org/10.1177/10760296231218216

Internet

https://doi.org/10.1177/10760296231218216

Similar Items